RESUMEN

This clinico-laboratory study showed that antihypoxant remaxol promoted normalization of lipid metabolism in acute peritonitis and significantly reduced membrane-destabilizing events. This resulted in rapid elimination of the inflammatory process in the abdominal cavity and lowering of the intensity of endogenous intoxication. This beneficial effect decreased the severity of myocardial lesions and resulted in the normalization of erythrocyte function. It is concluded that the regulatory action of remaxol on lipid metabolism is due to its ability to control free radicals in lipid peroxidation and reduce phospholipase A2 activity.

Asunto(s)

Metabolismo de los Lípidos/efectos de los fármacos , Miocardio/patología , Peritonitis/tratamiento farmacológico , Succinatos/uso terapéutico , Enfermedad Aguda , Eritrocitos/metabolismo , Radicales Libres/metabolismo , Humanos , Peroxidación de Lípido/efectos de los fármacos , Peritonitis/fisiopatología , Fosfolipasas A2/metabolismo , Índice de Severidad de la Enfermedad